Filgotinib

Summary

Filgotinib (CHEMBL3301607) is an approved small molecule (ATC L04AF04) targeting JAK1, JAK2, and JAK3; indicated across 13 conditions including rheumatoid arthritis and crohn disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L04AF04
• Targets: 4 (JAK1, JAK2, JAK3…)
• Indications: 13 conditions
• Clinical trials: 53
• Chemistry: 425.5 Da · C21H23N5O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3301607
Name	Filgotinib
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	49831257
ATC	L04AF04
Molecular formula	C21H23N5O3S
Molecular weight	425.5
InChIKey	RIJLVEAXPNLDTC-UHFFFAOYSA-N

SMILES: C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5

IUPAC name: N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide

Also known as: Filgotinib, G-146034, G146034, Glpg-0634, GLPG0634, GS-6034 FREE BASE, FILGOTINIB, GLPG-0634, G-146034_101, FILGOTINIB HYDROCHLORIDE, FILGOTINIB (GLPG0634), SID174006711

Parent form; salt/anhydrous children: CHEMBL3301602, CHEMBL4298167

Patent coverage: 1,082 distinct patent families (2,905 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
JAK1	Janus kinase 1	Inhibition	7.96	2.8%	P23458
JAK2	Janus kinase 2	Inhibition	5.62	0.7%	O60674
JAK3	Janus kinase 3	Inhibition	6.52	0.6%	P52333
TYK2	tyrosine kinase 2	Inhibition	5.59	0.8%	P29597

Broader ChEMBL bioactivity targets: 29 (assay-derived). Sample: Macrophage colony-stimulating factor 1 receptor, Tyrosine-protein kinase ABL1, Vascular endothelial growth factor receptor 1, Vascular endothelial growth factor receptor 3, Receptor-type tyrosine-protein kinase FLT3, Tyrosine-protein kinase JAK3, Voltage-gated inwardly rectifying potassium channel KCNH2, Mitogen-activated protein kinase 10, Tyrosine-protein kinase JAK1, Tyrosine-protein kinase JAK2, JAK3/JAK1, JAK2/JAK1, JAK1/JAK2/TYK2, JAK1/TYK2, JAK2/TYK2, Cytochrome P450 1A2, Interleukin-1 receptor-associated kinase 1, Non-receptor tyrosine-protein kinase TYK2, Cytochrome P450 2C19, AP2-associated protein kinase 1.

Bioactivity

ChEMBL activities: 167 potent at pChembl ≥ 5 of 178 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
JAK1	8.95	IC50	1.13	nM	CHEMBL_ACT_26279130
JAK1	8	IC50	10	nM	CHEMBL_ACT_15112128
JAK1	8	IC50	10	nM	CHEMBL_ACT_15747173
JAK1	8	IC50	10	nM	CHEMBL_ACT_18722535
JAK1	8	IC50	10	nM	CHEMBL_ACT_24788519
JAK1	8	IC50	10	nM	CHEMBL_ACT_24954209
JAK1	8	IC50	10	nM	CHEMBL_ACT_25044315
JAK1	8	IC50	10	nM	CHEMBL_ACT_25555172
JAK1	8	IC50	10	nM	CHEMBL_ACT_25848292
JAK1	8	IC50	10	nM	CHEMBL_ACT_26279080
JAK1	7.96	Kd	11	nM	CHEMBL_ACT_24958046
JAK1	7.96	Kd	11	nM	CHEMBL_ACT_26279084
JAK1	7.78	IC50	16.5	nM	CHEMBL_ACT_25675095
JAK2	7.6	IC50	25	nM	CHEMBL_ACT_15747169
JAK2	7.6	IC50	25	nM	CHEMBL_ACT_26279081
JAK1	7.58	IC50	26.2	nM	CHEMBL_ACT_22809389
JAK2	7.55	IC50	28	nM	CHEMBL_ACT_18722582
JAK2	7.55	IC50	28	nM	CHEMBL_ACT_24788497
JAK2	7.55	IC50	28	nM	CHEMBL_ACT_24954210
JAK2	7.55	IC50	28	nM	CHEMBL_ACT_25044316
JAK2	7.55	IC50	28	nM	CHEMBL_ACT_25555173
JAK2	7.55	IC50	28	nM	CHEMBL_ACT_25848298
JAK2	7.5	IC50	31.37	nM	CHEMBL_ACT_16308961
JAK2	7.5	Kd	32	nM	CHEMBL_ACT_24958047
JAK2	7.5	Kd	32	nM	CHEMBL_ACT_26279085
JAK2	7.5	IC50	31.4	nM	CHEMBL_ACT_28337330
JAK1	7.48	IC50	33	nM	CHEMBL_ACT_24875751
JAK2	7.39	IC50	41.16	nM	CHEMBL_ACT_16264194
JAK1	7.34	IC50	46	nM	CHEMBL_ACT_28650065
JAK1	7.33	IC50	47.07	nM	CHEMBL_ACT_16329737
JAK1	7.33	IC50	47.1	nM	CHEMBL_ACT_28337297
JAK1	7.32	IC50	48.29	nM	CHEMBL_ACT_16320054
JAK1	7.3	IC50	50.1	nM	CHEMBL_ACT_16272805
JAK1	7.3	IC50	50	nM	CHEMBL_ACT_26981407
JAK1	7.3	IC50	50	nM	CHEMBL_ACT_28012808
JAK1	7.3	IC50	50	nM	CHEMBL_ACT_28111484
JAK1	7.3	IC50	50.3	nM	CHEMBL_ACT_28249775
JAK1	7.3	IC50	50	nM	CHEMBL_ACT_28568312
JAK2	7.26	IC50	55.49	nM	CHEMBL_ACT_16336150
JAK2	7.26	IC50	55	nM	CHEMBL_ACT_28650068
JAK1	7.25	IC50	55.66	nM	CHEMBL_ACT_16260032
TYK2	7.18	IC50	65.3	nM	CHEMBL_ACT_22809518
TYK2	7.14	IC50	72.7	nM	CHEMBL_ACT_16312063
TYK2	7.14	IC50	72.7	nM	CHEMBL_ACT_28337366
TYK2	7.13	IC50	73.75	nM	CHEMBL_ACT_16329115
JAK2	7.13	IC50	74	nM	CHEMBL_ACT_20687210
JAK2	7.13	IC50	74	nM	CHEMBL_ACT_28012811
JAK2	7.13	IC50	73.4	nM	CHEMBL_ACT_28249778
TYK2	7.11	IC50	78	nM	CHEMBL_ACT_28249784
TYK2	7.1	IC50	79.07	nM	CHEMBL_ACT_16309230
TYK2	7.06	IC50	86.77	nM	CHEMBL_ACT_16265865
TYK2	6.95	IC50	113	nM	CHEMBL_ACT_24875865
TYK2	6.95	IC50	111.7	nM	CHEMBL_ACT_25675068
TYK2	6.94	IC50	116	nM	CHEMBL_ACT_15747161
TYK2	6.94	IC50	116	nM	CHEMBL_ACT_18722634
JAK1	6.94	IC50	115	nM	CHEMBL_ACT_20687196
TYK2	6.94	IC50	116	nM	CHEMBL_ACT_24958049
TYK2	6.94	IC50	116	nM	CHEMBL_ACT_24958050
TYK2	6.94	IC50	116	nM	CHEMBL_ACT_25044318
TYK2	6.94	IC50	116	nM	CHEMBL_ACT_25555175
TYK2	6.94	IC50	116	nM	CHEMBL_ACT_25848306
TYK2	6.94	IC50	116	nM	CHEMBL_ACT_26279083
JAK2	6.91	IC50	122	nM	CHEMBL_ACT_24875789
JAK1	6.83	IC50	148	nM	CHEMBL_ACT_15116678
JAK3	6.83	IC50	149.3	nM	CHEMBL_ACT_16351799
JAK1	6.83	IC50	148	nM	CHEMBL_ACT_26279092
JAK3	6.83	IC50	149	nM	CHEMBL_ACT_28337357
JAK1	6.81	IC50	154	nM	CHEMBL_ACT_15116677
JAK1	6.81	IC50	154	nM	CHEMBL_ACT_26279089
JAK2	6.78	IC50	167.3	nM	CHEMBL_ACT_16338363
JAK2	6.77	IC50	171	nM	CHEMBL_ACT_22809433
JAK1	6.75	IC50	178	nM	CHEMBL_ACT_24953747
JAK1	6.75	IC50	177.8	nM	CHEMBL_ACT_26279090
JAK3	6.75	IC50	180	nM	CHEMBL_ACT_28012814
JAK3	6.75	IC50	180	nM	CHEMBL_ACT_28249781
JAK3	6.73	IC50	187.3	nM	CHEMBL_ACT_16292529
JAK2	6.73	IC50	184.9	nM	CHEMBL_ACT_25675135
JAK3	6.72	IC50	189.3	nM	CHEMBL_ACT_16275767
JAK3	6.71	IC50	194.7	nM	CHEMBL_ACT_16291702
JAK3	6.69	IC50	203	nM	CHEMBL_ACT_26279091
FLT4	6.56	IC50	274	nM	CHEMBL_ACT_15116721
FLT4	6.56	IC50	274	nM	CHEMBL_ACT_24958045
FLT4	6.56	IC50	274	nM	CHEMBL_ACT_26279194
JAK3	6.52	Kd	300	nM	CHEMBL_ACT_24958048
JAK3	6.52	Kd	300	nM	CHEMBL_ACT_26279086
JAK1	6.51	IC50	306.2	nM	CHEMBL_ACT_24876145
FLT3	6.47	IC50	338	nM	CHEMBL_ACT_15116720
FLT3	6.47	IC50	338	nM	CHEMBL_ACT_24958044
FLT3	6.47	IC50	338	nM	CHEMBL_ACT_26279193
JAK1	6.46	IC50	346.7	nM	CHEMBL_ACT_26279093
JAK1	6.44	IC50	363	nM	CHEMBL_ACT_14751995
JAK2	6.39	IC50	407.4	nM	CHEMBL_ACT_24876139
JAK1	6.36	IC50	436	nM	CHEMBL_ACT_15116679
JAK1	6.36	IC50	436	nM	CHEMBL_ACT_26279094
JAK2	6.34	IC50	460	nM	CHEMBL_ACT_26981410
JAK2	6.34	IC50	460	nM	CHEMBL_ACT_28111487
JAK2	6.34	IC50	460	nM	CHEMBL_ACT_28568315
JAK1	6.33	IC50	467.7	nM	CHEMBL_ACT_26279095
CSF1R	6.31	IC50	489	nM	CHEMBL_ACT_15116722
CSF1R	6.31	IC50	488.9	nM	CHEMBL_ACT_24958043

Target pathways

Aggregated over 4 target gene(s): JAK1, JAK2, JAK3, TYK2.

Top Reactome pathways

86 total, by targets touching each:

Pathway	Targets	Genes
Interleukin-4 and Interleukin-13 signaling	4	JAK1, JAK2, JAK3, TYK2
Interleukin-20 family signaling	4	JAK1, JAK2, JAK3, TYK2
Potential therapeutics for SARS	4	JAK1, JAK2, JAK3, TYK2
Interleukin-6 signaling	3	JAK1, JAK2, TYK2
MAPK3 (ERK1) activation	3	JAK1, JAK2, TYK2
MAPK1 (ERK2) activation	3	JAK1, JAK2, TYK2
Cytokine Signaling in Immune system	3	JAK1, JAK2, JAK3
Signal Transduction	3	JAK1, JAK2, JAK3
Disease	3	JAK1, JAK2, JAK3
Immune System	3	JAK1, JAK2, JAK3
Signaling by Interleukins	3	JAK1, JAK2, JAK3
Interleukin-2 family signaling	3	JAK1, JAK2, JAK3
Interleukin-3, Interleukin-5 and GM-CSF signaling	3	JAK1, JAK2, JAK3
Infectious disease	3	JAK1, JAK2, JAK3
RAF/MAP kinase cascade	3	JAK1, JAK2, JAK3
MAPK family signaling cascades	3	JAK1, JAK2, JAK3
MAPK1/MAPK3 signaling	3	JAK1, JAK2, JAK3
IL-6-type cytokine receptor ligand interactions	3	JAK1, JAK2, TYK2
Interleukin-35 Signalling	3	JAK1, JAK2, TYK2
Interleukin-12 signaling	3	JAK1, JAK2, TYK2
Interleukin-27 signaling	3	JAK1, JAK2, TYK2
Interleukin receptor SHC signaling	3	JAK1, JAK2, JAK3
Signaling by CSF3 (G-CSF)	3	JAK1, JAK2, TYK2
SARS-CoV Infections	3	JAK1, JAK2, JAK3
Inactivation of CSF3 (G-CSF) signaling	3	JAK1, JAK2, TYK2
Viral Infection Pathways	3	JAK1, JAK2, JAK3
Activation of STAT3 by cadherin engagement	3	JAK1, JAK2, TYK2
RAF-independent MAPK1/3 activation	2	JAK1, JAK2
Interleukin-7 signaling	2	JAK1, JAK3
Interleukin-12 family signaling	2	JAK1, JAK2
Other interleukin signaling	2	JAK1, TYK2
Interleukin-6 family signaling	2	JAK1, JAK2
Interleukin-10 signaling	2	JAK1, TYK2
Interferon gamma signaling	2	JAK1, JAK2
Regulation of IFNG signaling	2	JAK1, JAK2
Interleukin-15 signaling	2	JAK1, JAK3
Interleukin-9 signaling	2	JAK1, JAK3
Signaling by Receptor Tyrosine Kinases	2	JAK2, JAK3
Interleukin-2 signaling	2	JAK1, JAK3
Interleukin-23 signaling	2	JAK2, TYK2
Interleukin-21 signaling	2	JAK1, JAK3
Interferon alpha/beta signaling	2	JAK1, TYK2
Regulation of IFNA/IFNB signaling	2	JAK1, TYK2
Interferon Signaling	2	JAK1, JAK2
SARS-CoV-2 activates/modulates innate and adaptive immune responses	2	JAK1, TYK2
IFNG signaling activates MAPKs	2	JAK1, JAK2
Evasion by RSV of host interferon responses	2	JAK1, TYK2
Hemostasis	1	JAK2
ISG15 antiviral mechanism	1	JAK1
Antimicrobial mechanism of IFN-stimulated genes	1	JAK1

Dominant GO biological processes

GO term	Targets
protein phosphorylation	4
cell surface receptor signaling pathway via JAK-STAT	4
cytokine-mediated signaling pathway	4
cell differentiation	4
intracellular signal transduction	4
growth hormone receptor signaling pathway via JAK-STAT	4
regulation of cell-cell adhesion	4
type II interferon-mediated signaling pathway	3
cellular response to virus	3
regulation of receptor signaling pathway via JAK-STAT	3
regulation of alpha-beta T cell activation	3
interleukin-15-mediated signaling pathway	2
interleukin-4-mediated signaling pathway	2
interleukin-2-mediated signaling pathway	2
interleukin-7-mediated signaling pathway	2

Indications & clinical

Indications

13 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
rheumatoid arthritis	3	MONDO:0008383	EFO:0000685
Crohn disease	3	MONDO:0005011	EFO:0000384
ulcerative colitis	3	MONDO:0005101	EFO:0000729
psoriatic arthritis	3	MONDO:0011849	EFO:0003778
ankylosing spondylitis	3	MONDO:0005306	EFO:0003898
spondyloarthropathy	3	MONDO:0005095	EFO:0000706
Sjogren syndrome	2	MONDO:0010030	EFO:0000699
cutaneous lupus erythematosus	2	MONDO:0005282	EFO:0003834
uveitis	2	MONDO:0020283	EFO:1001231
inflammatory bowel disease	2	MONDO:0005265	EFO:0003767
systemic lupus erythematosus	2	MONDO:0007915	MONDO:0007915
kidney disorder	1	MONDO:0005240	EFO:0003086
juvenile idiopathic arthritis	1	MONDO:0011429	EFO:0002609

Clinical trials

Total trials: 53.

Phase distribution

Phase	Trials
PHASE2	19
PHASE3	18
PHASE1	9
PHASE4	4
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04985435	PHASE4	RECRUITING	Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)
NCT06527534	PHASE4	RECRUITING	Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)
NCT06687551	PHASE4	NOT_YET_RECRUITING	JAK Inhibitor Dose TAPering Strategy Study
NCT05502731	PHASE4	UNKNOWN	Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis
NCT02914535	PHASE3	ACTIVE_NOT_RECRUITING	Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
NCT05785611	PHASE3	ACTIVE_NOT_RECRUITING	A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
NCT06865417	PHASE3	RECRUITING	A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
NCT07553182	PHASE3	RECRUITING	OLE Study With Filgotinib in JIA
NCT07554495	PHASE3	NOT_YET_RECRUITING	Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
NCT02873936	PHASE3	COMPLETED	Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
NCT02886728	PHASE3	COMPLETED	Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
NCT02889796	PHASE3	COMPLETED	Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
NCT02914522	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
NCT02914561	PHASE3	COMPLETED	Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn’s Disease
NCT02914600	PHASE3	TERMINATED	Filgotinib in Long-Term Extension Study of Adults With Crohn’s Disease
NCT03025308	PHASE3	COMPLETED	Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
NCT04115748	PHASE3	TERMINATED	Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
NCT04115839	PHASE3	TERMINATED	Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
NCT04483687	PHASE3	WITHDRAWN	Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy
NCT04483700	PHASE3	WITHDRAWN	Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy
NCT05090410	PHASE3	UNKNOWN	Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
NCT05479058	PHASE3	TERMINATED	A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission
NCT06285539	PHASE2	RECRUITING	Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
NCT01384422	PHASE2	COMPLETED	Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
NCT01668641	PHASE2	COMPLETED	Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
NCT01888874	PHASE2	COMPLETED	Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)
NCT01894516	PHASE2	COMPLETED	Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)
NCT02048618	PHASE2	COMPLETED	Efficacy and Safety of GLPG0634 in Subjects With Active Crohn’s Disease
NCT02065700	PHASE2	COMPLETED	Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants
NCT02885181	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate
NCT03046056	PHASE2	COMPLETED	Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD)
NCT03077412	PHASE2	COMPLETED	Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn’s Disease
NCT03100942	PHASE2	COMPLETED	Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren’s Syndrome
NCT03101670	PHASE2	COMPLETED	A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis
NCT03117270	PHASE2	COMPLETED	A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis
NCT03134222	PHASE2	COMPLETED	Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
NCT03201445	PHASE2	TERMINATED	Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
NCT03207815	PHASE2	TERMINATED	Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis
NCT03285711	PHASE2	COMPLETED	Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
NCT03320876	PHASE2	TERMINATED	An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.
NCT03926195	PHASE2	COMPLETED	Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis
NCT06222034	PHASE1	RECRUITING	Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
NCT01179581	PHASE1	COMPLETED	First-in-Human Single Ascending and Multiple Dose of GLPG0634
NCT01419990	PHASE1	COMPLETED	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects
NCT01798979	PHASE1	COMPLETED	A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects
NCT02084199	PHASE1	COMPLETED	Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects
NCT02162355	PHASE1	COMPLETED	Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects
NCT03417778	PHASE1	COMPLETED	Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function
NCT04608344	PHASE1	COMPLETED	Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants
NCT06043739	PHASE1	COMPLETED	Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects
NCT04871919	Not specified	ACTIVE_NOT_RECRUITING	Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
NCT05817942	Not specified	ACTIVE_NOT_RECRUITING	Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
NCT05323591	Not specified	COMPLETED	Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

126 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
DEUCRAVACITINIB	ChEMBL + PubChem	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
Pazopanib	ChEMBL + PubChem	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
RITLECITINIB	ChEMBL + PubChem	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
ABROCITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
BARICITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
FEDRATINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
MOMELOTINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
NINTEDANIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
PACRITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
PEFICITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
RUXOLITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
SUNITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
TOFACITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
UPADACITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3, TYK2
BREPOCITINIB	ChEMBL	Phase 3	JAK1, JAK2, JAK3, TYK2
DELGOCITINIB	ChEMBL	Phase 3	JAK1, JAK2, JAK3, TYK2
DOVITINIB	ChEMBL	Phase 3	JAK1, JAK2, JAK3, TYK2
ITACITINIB	ChEMBL	Phase 3	JAK1, JAK2, JAK3, TYK2
LESTAURTINIB	ChEMBL	Phase 3	JAK1, JAK2, JAK3, TYK2
AT-9283	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
ATINVICITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
AZD-1480	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
BMS-911543	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
CC-401	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
CERDULATINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
DECERNOTINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
GANDOTINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
GOLIDOCITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
GUSACITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
IFIDANCITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
IZENCITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
NEZULCITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
NS-018	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
OCLACITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
R-406	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
ROPSACITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
SOLCITINIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
SU-014813	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
TOZASERTIB	ChEMBL	Phase 2	JAK1, JAK2, JAK3, TYK2
Afatinib	PubChem	Approved	JAK1, JAK2, JAK3, TYK2
Gefitinib	PubChem	Approved	JAK1, JAK2, JAK3, TYK2
Idelalisib	PubChem	Approved	JAK1, JAK2, JAK3, TYK2
Selumetinib	PubChem	Approved	JAK1, JAK2, JAK3, TYK2
dacomitinib	ChEMBL + PubChem	Phase 4 (approved)	JAK1, JAK3, TYK2
IMATINIB	ChEMBL + PubChem	Phase 4 (approved)	JAK1, JAK2, TYK2
AXITINIB	ChEMBL	Phase 4 (approved)	JAK2, JAK3, TYK2
BOSUTINIB	ChEMBL	Phase 4 (approved)	JAK2, JAK3, TYK2
CERITINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3
DASATINIB	ChEMBL	Phase 4 (approved)	JAK2, JAK3, TYK2
ENTRECTINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2, JAK3
ERLOTINIB	ChEMBL	Phase 4 (approved)	JAK2, JAK3, TYK2
ABIVERTINIB	ChEMBL	Phase 3	JAK1, JAK2, JAK3
ALVOCIDIB	ChEMBL	Phase 3	JAK2, JAK3, TYK2
DEFACTINIB	ChEMBL	Phase 3	JAK2, JAK3, TYK2
BMS-919373	ChEMBL	Phase 2	JAK2, JAK3, TYK2
CENISERTIB	ChEMBL	Phase 2	JAK2, JAK3, TYK2
LONDAMOCITINIB	ChEMBL	Phase 2	JAK1, JAK2, TYK2
belumosudil	PubChem	Approved	JAK2, JAK3, TYK2
Fostamatinib	PubChem	Approved	JAK1, JAK2, TYK2
Trametinib	PubChem	Approved	JAK1, JAK2, TYK2
CRAVACITINIB	ChEMBL	Phase 4 (approved)	JAK2, TYK2
INFIGRATINIB	ChEMBL	Phase 4 (approved)	JAK2, TYK2
PONATINIB	ChEMBL	Phase 4 (approved)	JAK1, JAK2
IVARMACITINIB	ChEMBL	Phase 3	JAK1, JAK2
POVORCITINIB	ChEMBL	Phase 3	JAK1, JAK2
ADAVOSERTIB	ChEMBL	Phase 2	JAK2, JAK3
FORETINIB	ChEMBL	Phase 2	JAK2, TYK2
ILORASERTIB	ChEMBL	Phase 2	JAK2, TYK2
LAUROGUADINE	ChEMBL	Phase 2	JAK2, JAK3
LEPZACITINIB	ChEMBL	Phase 2	JAK1, JAK3
PELITINIB	ChEMBL	Phase 2	JAK2, JAK3
PICTILISIB	ChEMBL	Phase 2	JAK1, TYK2
REBASTINIB	ChEMBL	Phase 2	JAK1, JAK2
SOTRASTAURIN	ChEMBL	Phase 2	JAK1, JAK3
SPEBRUTINIB	ChEMBL	Phase 2	JAK2, JAK3
TG100-115	ChEMBL	Phase 2	JAK1, TYK2
ZOTIRACICLIB	ChEMBL	Phase 2	JAK1, JAK2
Binimetinib	PubChem	Approved	JAK1, TYK2
regorafenib	PubChem	Approved	JAK1, TYK2
ACALABRUTINIB	ChEMBL	Phase 4 (approved)	JAK3
BRIGATINIB	ChEMBL	Phase 4 (approved)	JAK2
DABRAFENIB	ChEMBL	Phase 4 (approved)	JAK2
IBRUTINIB	ChEMBL	Phase 4 (approved)	JAK3
LORLATINIB	ChEMBL	Phase 4 (approved)	JAK2
NERATINIB	ChEMBL	Phase 4 (approved)	JAK3
NICLOSAMIDE	ChEMBL	Phase 4 (approved)	JAK2
OSIMERTINIB	ChEMBL	Phase 4 (approved)	JAK3
PALBOCICLIB	ChEMBL	Phase 4 (approved)	JAK3
PRALSETINIB	ChEMBL	Phase 4 (approved)	JAK2
REPOTRECTINIB	ChEMBL	Phase 4 (approved)	JAK2
SORAFENIB	ChEMBL	Phase 4 (approved)	JAK3
TRIAMTERENE	ChEMBL	Phase 4 (approved)	JAK2
ZANUBRUTINIB	ChEMBL	Phase 4 (approved)	JAK3
CANERTINIB	ChEMBL	Phase 3	JAK3
DACTOLISIB	ChEMBL	Phase 3	JAK3
ENTOSPLETINIB	ChEMBL	Phase 3	JAK2
ENZASTAURIN	ChEMBL	Phase 3	JAK3
MOTESANIB	ChEMBL	Phase 3	JAK1